Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T cell therapy shows efficacy in B cell malignancies and multiple myeloma.
• Approved CAR T cell products face limitations: high cost, variable quality, contamination, manufacturing failures, and production delays.

Purpose of the Study:

• To review challenges and strategies for developing allogeneic CAR T cell therapies.
• To address barriers hindering the broad application of current CAR T cell treatments.

Main Methods:

• Discussing graft-versus-host disease (GVHD) and immune rejection.
• Summarizing gene editing technologies and alternative cell sources for allogeneic CAR T cells.

Main Results:

• Allogeneic CAR T cells present a potential solution to limitations of autologous CAR T cells.
• Gene editing and novel cell sources are being explored to overcome therapeutic hurdles.

Conclusions:

• Developing safe and effective allogeneic CAR T cell therapies requires addressing GVHD and immune rejection.
• Innovative approaches are crucial for advancing off-the-shelf CAR T cell treatments for hematologic malignancies.